Research programme: casein kinase II inhibitors - Cylene
Alternative Names: CK-5011; CK2 inhibitors; CX-5011; CX-8184Latest Information Update: 24 Dec 2013
At a glance
- Originator Cylene Pharmaceuticals
- Class Small molecules
- Mechanism of Action Casein kinase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Jan 2013 Discontinued - Preclinical for Cancer in USA (PO)
- 04 Apr 2012 Research programme: casein kinase II inhibitors is still in preclinical development for Cancer in USA
- 03 Apr 2012 Pharmacodynamics and pharmacokinetics data from preclinical studies presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR-2012)